Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Viardot

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
Annals of Hematology|February 12, 2022
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 yearsKathrin Rieger, Rosaria De Filippi, Ola Lindén, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Clinicopathologic correlations of genomic gains and losses in follicular lymphomaAndreas Viardot, Peter Möller, Josef Högel, et al.
Blood Advances|January 13, 2022
Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methodsMichaela Kotrová, Johannes Koopmann, Heiko Trautmann, et al.
British Journal of Haematology|March 14, 2012
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphomaMyron S Czuczman, Georg Hess, Ole V Gadeberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trialChristian W Scholz, Antonello Pinto, Werner Linkesch, et al.
Leukemia & Lymphoma|December 10, 2020
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomasNina D Wagner-Johnston, Stephen J Schuster, Sven deVos, et al.
European Journal of Immunology|April 16, 2010
CD5+ B cells from individuals with systemic lupus erythematosus express granzyme BMagdalena Hagn, Verena Ebel, Kai Sontheimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvementGerhard Held, Samira Zeynalova, Niels Murawski, et al.
Scientific Reports|December 5, 2020
U-DCS: characterization of the first permanent human dendritic sarcoma cell lineKevin Mellert, Julian Benckendorff, Frank Leithäuser, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
Annals of Hematology|February 12, 2022
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 yearsKathrin Rieger, Rosaria De Filippi, Ola Lindén, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Clinicopathologic correlations of genomic gains and losses in follicular lymphomaAndreas Viardot, Peter Möller, Josef Högel, et al.
Blood Advances|January 13, 2022
Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methodsMichaela Kotrová, Johannes Koopmann, Heiko Trautmann, et al.
British Journal of Haematology|March 14, 2012
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphomaMyron S Czuczman, Georg Hess, Ole V Gadeberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trialChristian W Scholz, Antonello Pinto, Werner Linkesch, et al.
Leukemia & Lymphoma|December 10, 2020
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomasNina D Wagner-Johnston, Stephen J Schuster, Sven deVos, et al.
European Journal of Immunology|April 16, 2010
CD5+ B cells from individuals with systemic lupus erythematosus express granzyme BMagdalena Hagn, Verena Ebel, Kai Sontheimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvementGerhard Held, Samira Zeynalova, Niels Murawski, et al.
Scientific Reports|December 5, 2020
U-DCS: characterization of the first permanent human dendritic sarcoma cell lineKevin Mellert, Julian Benckendorff, Frank Leithäuser, et al.
Pageof 9